SFC Dual Filing Regime: Regulatory Review Powers Over IPO Prospectuses

The SFC’s dual filing regime under the Securities and Futures Ordinance (Cap. 571) is not a new concept, but its operational teeth have sharpened considerably in the 2024-2025 cycle. Since the 2023 amendments to the SFC’s Sponsor Regulation and the updated Listing Decisions published by HKEX in Q1 2025, the regulator has quietly escalated the frequency and depth of its substantive review of IPO prospectuses before they reach the market. This shift, driven by a post-2022 wave of enforcement actions targeting deficient disclosures in Main Board and GEM listings, has fundamentally altered the timeline and risk calculus for sponsors and issuers. The dual filing regime, where the SFC retains concurrent powers under Section 6 of the SFO to object to or suspend a listing even after HKEX has granted its “no further comments,” is no longer a theoretical backstop. It is now a live, pre-IPO gatekeeping mechanism that can add 4-6 weeks to the typical A1 submission-to-listing timeline, with direct implications for deal certainty and pricing windows.

The Statutory Framework: Dual Filing Under the SFO

The dual filing regime is codified in Part IV of the Securities and Futures Ordinance (Cap. 571), specifically Sections 5 and 6. Section 5 mandates that every issuer seeking a listing on HKEX must file a copy of its prospectus with the SFC within the same timeframe it is submitted to HKEX. This is not a mere administrative step. Section 6 grants the SFC the power to object to a prospectus if it contains any statement that is false, misleading, or deceptive in a material particular, or if it omits any material fact required under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32). The SFC’s power is not limited to post-listing enforcement; it can issue a “stop order” under Section 38B of the SFO, effectively freezing the listing process until the deficiency is rectified.

The 2023-2024 Enforcement Shift

Data from the SFC’s Annual Report 2024 (published July 2024) shows that the regulator reviewed 143 prospectuses under the dual filing regime in the fiscal year ending March 2024, up from 112 in FY2023. Of these, 27 resulted in formal “comments letters” requiring substantive revisions before HKEX could proceed with the listing hearing. This represents a 141% increase in prospectuses subjected to formal comments compared to the pre-pandemic average of 11 per year between 2018 and 2020. The SFC’s focus has been concentrated on three areas: (i) revenue recognition policies for technology and healthcare companies with complex contract arrangements; (ii) related-party transaction disclosures, particularly where the issuer operates through a BVI or Cayman holding structure with PRC operating subsidiaries; and (iii) the adequacy of working capital statements for issuers with negative operating cash flows.

The Interaction with HKEX’s Listing Division

The dual filing regime operates on a parallel track. HKEX’s Listing Division conducts its own review under the Listing Rules, focusing on eligibility, suitability, and compliance with the Listing Rules (Main Board Rules, Chapters 8 and 9; GEM Rules, Chapters 11 and 12). The SFC’s review under the SFO is independent and can override HKEX’s preliminary approval. In practice, the SFC has delegated the initial review of routine prospectuses to HKEX under a Memorandum of Understanding (MOU) signed in 2003 and updated in 2018. However, the SFC retains the right to “call in” any prospectus for its own review. Since 2023, the SFC has exercised this call-in power more aggressively, particularly for issuers with a market capitalisation below HKD 500 million or those relying on the GEM transfer route to the Main Board. The SFC’s 2024 Enforcement Report notes that 18% of all prospectus comments issued in FY2024 were the result of a direct SFC call-in, not a referral from HKEX.

The Pre-IPO Review Process: Timeline and Mechanics

The dual filing regime imposes a mandatory “quiet period” of at least 10 business days after the prospectus is filed with the SFC before the listing hearing can be scheduled. This period is extendable at the SFC’s discretion. In practice, the SFC’s review timeline has lengthened. Data from HKEX’s Listing Statistics 2024 (published January 2025) indicates that the median time from A1 submission to the first hearing for Main Board IPOs was 68 business days in 2024, up from 52 business days in 2022. Of this increase, an estimated 12-14 business days are attributable to the SFC’s dual filing review, based on analysis of 45 IPO prospectuses that received SFC comments during the period.

The Comment Letter Cycle

The SFC’s comments are typically issued in two rounds. The first-round letter, received 15-20 business days after filing, addresses structural issues such as the adequacy of the working capital forecast, the completeness of the “Risk Factors” section, and the accuracy of the “Use of Proceeds” statement. The second-round letter, issued 5-10 business days after the sponsor’s response, focuses on residual disclosure gaps. For the 27 prospectuses that received formal comments in FY2024, the average number of comments per letter was 8.4, with a range of 3 to 22. The most common comment category was “Revenue Recognition” (cited in 62% of letters), followed by “Related-Party Transactions” (48%) and “Legal and Regulatory Compliance” (39%).

The “No Objection” Letter

The SFC does not issue an explicit approval. Instead, it issues a “no objection” letter under Section 5 of the SFO, confirming that it does not intend to exercise its powers under Section 6. This letter is a prerequisite for HKEX to schedule the listing hearing. The absence of this letter, or the receipt of an “objection” letter, effectively halts the listing. In 2024, the SFC issued two formal objection letters under Section 6. One case involved a PRC-based biotech issuer where the SFC determined that the prospectus failed to disclose material litigation against the founder in a PRC district court. The other case involved a GEM-listed company seeking a transfer to the Main Board, where the SFC found that the issuer’s revenue recognition policy for a software-as-a-service (SaaS) product did not comply with HKFRS 15. Both issuers withdrew their applications.

Practical Implications for Sponsors and Issuers

The dual filing regime’s heightened scrutiny has direct consequences for deal structuring and timeline management. Sponsors must now budget for a minimum of 14-16 weeks from A1 submission to the hearing, up from the historical 8-10 weeks. This extended timeline increases the risk of market window closure, particularly for issuers with a narrow pricing window tied to a specific earnings season or industry event.

Sponsor Liability and Due Diligence

The SFC’s 2023 Sponsor Regulation amendments, effective January 2024, explicitly require sponsors to document their due diligence procedures for verifying the accuracy of prospectus statements that the SFC is most likely to review. This includes a mandatory “SFC Due Diligence Checklist” that must be appended to the sponsor’s declaration filed under Section 6 of the SFO. The checklist must cover, at minimum: (i) revenue recognition policies for the top 10 customers; (ii) the legal ownership structure of the issuer’s BVI, Cayman, and PRC subsidiaries; and (iii) the issuer’s compliance with the PRC’s Cybersecurity Law and Data Security Law for any data-related business. Failure to complete this checklist can result in the SFC issuing a “deficiency notice” under the Code of Conduct for Persons Licensed by or Registered with the SFC (paragraph 17.2), which can delay the listing by 20-30 business days.

The Impact on Pricing and Valuation

The extended timeline under the dual filing regime also affects the pricing mechanics of the bookbuilding process. The SFC’s review period overlaps with the pre-marketing phase, meaning that the preliminary pricing range must be filed with the SFC as part of the prospectus. If the SFC’s comments require material changes to the business description or financial forecasts, the sponsor may need to re-file the prospectus with a revised pricing range, triggering a new 10-business day quiet period. This occurred in 8% of Main Board IPOs in 2024, according to HKEX’s Market Statistics 2024. In one notable case, a consumer goods issuer was forced to reduce its pricing range by 12% after the SFC required the inclusion of a new risk factor related to PRC regulatory changes in the e-commerce sector.

The Cross-Border Dimension: PRC and International Issuers

The dual filing regime’s impact is most pronounced for PRC-based issuers using the VIE structure. The SFC’s 2024 Guidance Note on VIE Structures in Listing Applications (published June 2024) explicitly states that the SFC will review the “economic substance” of the VIE arrangements under the dual filing regime, not just their legal form. This means the SFC will assess whether the VIE contracts provide the issuer with effective control over the PRC operating entity, and whether the prospectus adequately discloses the risks of PRC regulatory action against the VIE structure.

The PRC CSRC Filing Requirement

Since March 2023, PRC-based issuers must also file their prospectus with the China Securities Regulatory Commission (CSRC) under the Trial Administrative Measures of Overseas Securities Offerings and Listings by Domestic Companies. This creates a triple filing requirement: the issuer must file with HKEX, the SFC, and the CSRC. The CSRC’s review timeline is 20 business days, extendable by another 20 business days if the CSRC raises questions. The SFC and CSRC have no formal coordination mechanism, meaning that comments from one regulator can arrive after the other has already issued its clearance. This can lead to a “ping-pong” effect, where the issuer must revise the prospectus to address CSRC comments after the SFC has already issued its no-objection letter, potentially triggering a new SFC review cycle.

International Issuers and the SFC’s Reach

The dual filing regime applies equally to international issuers listing in Hong Kong, including those from Southeast Asia, the US, and Europe. The SFC’s review powers under Section 6 of the SFO are not limited by the issuer’s domicile. In 2024, the SFC issued comments on three prospectuses for international issuers, all of which involved complex revenue recognition issues under IFRS or US GAAP. In one case, a Singapore-based REIT seeking a secondary listing on the Main Board was required to restate its financial statements for the prior three fiscal years after the SFC determined that its treatment of property revaluation gains did not comply with HKFRS. The restatement caused a 6-month delay in the listing.

Key Takeaways for Market Participants

1. Budget for a 14-16 week timeline from A1 submission to listing hearing, and include contractual provisions in the underwriting agreement to allow for at least two rounds of SFC comments without triggering a material adverse change clause.
2. Prepare a dedicated SFC Due Diligence Checklist that covers revenue recognition, related-party transactions, and PRC regulatory compliance, and have it reviewed by external counsel before the prospectus is filed.
3. Monitor the SFC’s quarterly enforcement reports for emerging areas of scrutiny; the 2025 focus is expected to be on ESG-related disclosures and the adequacy of working capital statements for issuers with negative free cash flow.
4. Coordinate the CSRC and SFC filing timelines by filing with the CSRC at least 10 business days before the SFC filing, to allow the CSRC’s 20-business-day review period to run concurrently with the SFC’s initial 10-business-day quiet period.
5. Engage counsel with direct experience in SFC dual filing review for issuers using VIE structures or operating in regulated PRC sectors, as the SFC’s 2024 guidance note has increased the probability of a call-in review for these structures.